Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20592144 | 0.92 | NAMPT (0.48) | SMN1; SMN2KMT2AMEN1LMNALTA4H | |
| SCHEMBL18361286 | 0.88 | HDAC1 (0.55) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL20592161 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2AMEN1LMNALTA4H | |
| SCHEMBL18361285 | 0.85 | DRD2 (0.51) | SMN1; SMN2LMNALTA4HNAMPTHDAC1 | |
| SCHEMBL18361331 | 0.84 | HDAC1 (0.52) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL20592185 | 0.83 | HDAC1 (0.51) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL18361300 | 0.83 | HDAC1 (0.52) | NAMPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL20592115 | 0.83 | HDAC1 (0.42) | SMN1; SMN2KMT2AMEN1LMNAHDAC1 | |
| SCHEMBL18361336 | 0.82 | HDAC1 (0.53) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL18361372 | 0.82 | HDAC1 (0.53) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2018-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851058-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 4294/4885KMT2A 68/4885MEN1 4476/4885 |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 4294/4885KMT2A 68/4885MEN1 4476/4885 |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 4294/4885KMT2A 68/4885MEN1 4476/4885 |
| US-10308608-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 4294/4885KMT2A 68/4885MEN1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.